You are here

LentiGlobin

ASH 2021 – Bluebird looks to revive Lentiglobin

ASH 2021 – Bluebird looks to revive Lentiglobin

EP Vantage

sickle cell disease

Flag link:

With LentiGlobin cleared by FDA, bluebird lifts EU marketing hold on gene therapy using the same delivery mechanism

With LentiGlobin cleared by FDA, bluebird lifts EU marketing hold on gene therapy using the same delivery mechanism

Endpoints

sickle cell disease

beta thalassemia

Flag link:

Bluebird seeks gene therapy trial restart after cancer scare

Bluebird seeks gene therapy trial restart after cancer scare

Pharmaforum

sickle cell disease

Flag link:

EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder

EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder

EP Vantage

sickle cell disease

Flag link:

FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

Motley Fool

beta thalassemia

clinical trials

Flag link:

Bluebird says gene therapy application delayed again, citing disagreement with FDA

Bluebird says gene therapy application delayed again, citing disagreement with FDA

BioPharma Dive

Flag link:

LentiGlobin gene therapy for sickle cell on course for filing, says bluebird

LentiGlobin gene therapy for sickle cell on course for filing, says bluebird

Pharmaforum

sickle cell disease

Flag link:

Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

Motley Fool

Aimmune Therapeutics

Flag link:

Orphan drugs market to soar to $224bn by 2024

Orphan drugs market to soar to $224bn by 2024

PM Live

Evaluate Pharma

Flag link:

2 Blockbuster Gene Therapy Programs to Watch in 2019

2 Blockbuster Gene Therapy Programs to Watch in 2019

Motley Fool

Flag link:

First gene therapy to treat rare blood disease nears European approval

First gene therapy to treat rare blood disease nears European approval

Stat

beta-thalassemia

Flag link:

bluebird bio to Cut Ribbon on New Gene Therapy Factory in Durham, NC; Plans to Hire

bluebird bio to Cut Ribbon on New Gene Therapy Factory in Durham, NC; Plans to Hire

BioSpace

drug manufacturing

Flag link:

Where Will bluebird bio Be in 5 Years?

Where Will bluebird bio Be in 5 Years?

Motley Fool

Flag link:

bluebird's five-year pricing model for LentiGlobin could resonate with payers

bluebird's five-year pricing model for LentiGlobin could resonate with payers

BioCentury

Flag link:

EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

CP Wire

transfusion-dependent anemia

Flag link:

EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

transfusion-dependent anemia

Flag link:

Bluebird’s first gene therapy gets European fast track

Bluebird’s first gene therapy gets European fast track

PM Live

Flag link:

Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far

Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far

Motley Fool

beta thalassemia

Flag link:

Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives

Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives

Yahoo/Benzinga

Madrigal Pharmaceuticals

Flag link:

Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease

Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease

CP Wire

sickle cell disease

Flag link:

Pages